NCATS Drug Product Development Studies 2017-2022
Ended Master IDIQ Awarded
- Federal agency
-
National Institutes of Health
- Awardees
- 4
- Task orders
- 13
- Obligated
- $8,127,912
Vehicle facts
- Opportunity
-
- CRO Support for NCATS Drug Product Development, Manufacture, and Stability Studies Pre-Solicitation · N01TR172003 · Posted Jul 21, 2016
- Agency
-
- National Institutes of Health Department of Health and Human Services
- Combined task order value
-
- $8,133,523 Current, with exercised options
- $8,194,258 Potential, with all options
- Last date to order 100% complete
- Shared ceiling 56% used
- $14,444,775.00
IDV award and task order details come from SAM.gov/FPDS.
About this vehicle
The National Institutes of Health's National Center for Advancing Translational Science (NCATS) established this Master IDIQ on July 26, 2017 to procure contract research organization support for drug product development, manufacturing, and stability studies; ordering closed on July 31, 2022, and the vehicle is no longer active.
The vehicle funded NCATS's Division of Preclinical Innovation in moving small molecule and biologic drug candidates through the pre-clinical stage toward FDA Investigational New Drug (IND) filings and, where justified, into human Phase IIB clinical trials. Work included dosage form development, cGMP manufacturing, stability testing, and related analytical services for candidate therapies originating from academia, industry, non-profit foundations, and internal NCATS programs under initiatives such as Therapeutics for Rare and Neglected Diseases (TRND) and Bridging Interventional Development Gaps (BrIDGs). All 13 task orders awarded under the vehicle carried no set-aside designation.
Societal CDMO San Diego, LLC dominates the vehicle, holding 9 of 13 awarded orders and $6.3 million of the $8.2 million combined potential value—approximately 77 percent of activity by value. The University of Iowa and Purdue University hold two orders and one order, respectively, with Murty Pharmaceuticals accounting for the remainder. Obligated funding stands at $8.1 million against the $8.2 million potential value. NCATS itself placed seven orders representing $5 million in combined potential value; the National Institute on Drug Abuse placed four orders for $2.4 million; and the National Cancer Institute placed two orders for $790 thousand. Task-order values ranged from $32.6 thousand to $2.0 million, with firm fixed-price pricing predominating. Recent orders (2021 through May 2024) show signs of termination for convenience activity initiated under the Department of Government Efficiency cost efficiency initiative, with multiple orders terminated or partially terminated between March and April 2025. Performance periods extended through mid-2025, though the vehicle's ordering authority expired in July 2022.
Description
Contract research organizations (CRO) Support for National Center for Advancing Translational Science (NCATS) Drug Product Development, Manufacture, and Stability Studies.
IDV awards
Latest task orders
Show all 13
Top awardees by obligations
| Rank | Awardee | Obligated | Share |
|---|---|---|---|
| 1 | Societal Cdmo San Diego, LLC | $6,195,916 | 76% |
| 2 | The University Of Iowa | $1,081,559 | 13% |
| 3 | Purdue University | $704,709 | 9% |
| 4 | Murty Pharmaceuticals, Inc. | $145,728 | 2% |
Top funding agencies by obligations
| Rank | Funding agency | Obligated | Share |
|---|---|---|---|
| 1 | Department of Health and Human Services | $8,127,912 | 100% |
Obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2024 | $888,215 |
| FY2023 | $421,652 |
| FY2022 | $1,097,733 |
| FY2021 | $2,950,773 |
| FY2020 | $1,904,592 |
| FY2019 | $402,648 |
| FY2018 | $142,959 |
| FY2017 | $319,341 |
Quick answers
What is the NCATS Drug Product Development Studies 2017-2022 contract vehicle?
NCATS Drug Product Development Studies 2017-2022 is an indefinite delivery, indefinite quantity (IDIQ) contract vehicle run by National Institutes of Health (Department of Health and Human Services), awarded on July 26, 2017.
Which companies hold NCATS Drug Product Development Studies 2017-2022?
4 companies hold NCATS Drug Product Development Studies 2017-2022's IDV awards, one each. The latest went to The University Of Iowa on August 1, 2017. The awardees whose task orders obligated the most are Societal Cdmo San Diego, LLC, The University Of Iowa and Purdue University.
How much has been spent through NCATS Drug Product Development Studies 2017-2022?
13 task orders have been placed under NCATS Drug Product Development Studies 2017-2022, obligating $8,127,912. Their combined current value, with exercised options, is $8,133,523.
What is the shared ceiling of NCATS Drug Product Development Studies 2017-2022?
NCATS Drug Product Development Studies 2017-2022's shared ceiling is $14,444,775; its task orders have used 56% of it.
Which agencies use NCATS Drug Product Development Studies 2017-2022 the most?
The departments whose task orders under NCATS Drug Product Development Studies 2017-2022 obligated the most are Department of Health and Human Services ($8,127,912).
On GovTribe
See this vehicle's full record
- Every IDV award and task order
- Funding by agency, awardee, NAICS and set-aside
- Teaming partners on this vehicle
- Ask GovTribe AI about this vehicle